Neonatal Surfactant Therapy Market Trends, Industry | 2032

Report Description

Market Outlook:

The global neonatal surfactant therapy market was valued at USD 675.4 Million in 2023 and is anticipated to reach USD 1,077.5 Million by 2032, expanding at a CAGR of 5.5% during the forecast period.

Neonatal surfactant therapy is a life-saving medical treatment for premature babies born with respiratory distress syndrome (RDS). RDS is a common condition affecting infants born before their lungs are fully developed. These underdeveloped lungs lack sufficient amounts of a substance called surfactant, which is a natural lining produced by the lungs that helps the alveoli (air sacs) stay inflated.

Get Free Sample Report

Surfactant acts as a lubricant, reducing the surface tension within the alveoli, and preventing them from collapsing during exhalation. Surfactant works by reducing the surface tension of the fluid lining the alveoli. This improves gas exchange, allowing oxygen to enter the bloodstream and remove carbon dioxide. Surfactant is typically delivered through a thin catheter inserted into the trachea (windpipe) while the baby is on continuous positive airway pressure (CPAP) support. Continuous positive airway pressure (CPAP) mask provides a constant flow of air to help keep the airways open. Neonatal surfactant therapy has been a major breakthrough in neonatal care, significantly improving the survival rates of premature babies with RDS.

Impact of COVID-19:

The research report finds that the outbreak of COVID-19 had a moderate impact on the market. The market was affected during the initial phase of the pandemic, leading to short-term disruptions. However, factors such as the rising premature birth rates and advancements in surfactant therapy technology propelled the market post-Covid-19.

The pandemic heightened awareness about respiratory illnesses, potentially leading to early diagnoses and interventions for newborns with breathing problems. The rise of telemedicine during the COVID-19 pandemic improved access to consultations with neonatal specialists for hospitals, impacting treatment decisions for surfactant therapy.

Artificial Intelligence (AI) Impact on the Neonatal Surfactant Therapy Market:

Artificial intelligence (AI) has a significant impact on the neonatal surfactant therapy market. AI analyzes chest X-rays and other medical images to identify early signs of RDS, enabling early intervention with surfactant therapy. This significantly reduces the chances of premature birth. AI-powered continuous monitoring systems track vital signs and physiological parameters, allowing for early detection of RDS worsening and prompting timely adjustments in treatment. AI algorithms analyze data such as lung function tests and blood gas levels to predict the risk of RDS with high accuracy. This helps doctors decide if surfactant therapy is necessary, potentially reducing unnecessary use and costs.

AI personalizes surfactant dosing based on individual infant characteristics, optimizing treatment effectiveness and minimizing side effects. AI performs early and accurate diagnosis of arrhythmias allowing for prompt intervention and improved patient outcomes. It helps reduce false positives, minimizing unnecessary investigations and anxiety for patients.

Market Dynamics

Market Driver- Rising Prevalence of Premature Births

Premature babies often have underdeveloped lungs, which lack sufficient production of surfactant. Premature birth is a major risk factor for neonatal respiratory distress syndrome (NRDS).

According to the World Health Organization, an estimated 13.4 million babies were born preterm in 2020, accounting for nearly 1 in 10 births across the globe. Preterm birth complications are the key cause of death among children under 5 years of age, responsible for approximately 900,000 deaths in 2019. Globally, the rate of preterm birth ranges from 4-16% of babies born in 2020.

The increasing rate of premature births is attributed to factors such as multiple pregnancies, assisted reproductive technology, and maternal health problems. Surfactant therapy has revolutionized the care of premature infants. It is highly effective in reducing the severity of RDS, lessening the need for mechanical ventilation, and improving survival rates. This established efficacy is driving the demand for surfactant therapy in neonatal care units across the globe.

Market Driver- Growing Awareness of NRDS and Surfactant Therapy

Neonatal respiratory distress syndrome (NRDS) is a serious lung condition affecting premature infants. Growing awareness among healthcare professionals and parents about NRDS symptoms and the benefits of surfactant therapy are major factors driving the market. Educational campaigns and initiatives by healthcare organizations and patient advocacy groups are playing a crucial role in spreading awareness. Increased access to prenatal care, particularly in developing regions, also contributes to early diagnosis and treatment of NRDS, leading to a high demand for surfactant therapy. Thus, the rising awareness of neonatal surfactant therapy is expected to drive the market during the forecast period.

Market Restraint- Limited Availability in Developing Countries

Limited availability of surfactant therapy remains a major concern in developing regions. The lack of well-equipped neonatal intensive care units (NICUs) and trained healthcare professionals hinder access to this specialized treatment. The high cost of surfactant therapy creates barriers for consumers in low- and middle-income countries, limiting its accessibility for many infants in need.

Complexities in cold chain logistics make it difficult to ensure proper storage and transportation of temperature-sensitive surfactant medications in resource-limited settings. Thus, the limited availability of neonatal surfactant therapy in developing countries restrains the market.

Market Opportunity- Rising Advancements in Neonatal Surfactant Therapy

Continuous advancements in neonatal surfactant therapy led to enhanced safety, and accuracy. The field of neonatal surfactant therapy is constantly evolving, with technologies emerging to improve treatment outcomes for premature infants. Researchers are developing methods to deliver surfactants directly to the affected areas of the lungs, maximizing their effectiveness and minimizing overall dosage.

Gene therapy holds promise for potentially treating or even preventing NRDS by introducing healthy genes that help the lungs produce natural surfactants. Thus, advancement in neonatal surfactant therapy is expected to create lucrative opportunities in the market during the forecast period.

Scope of the Report  

The report on the global neonatal surfactant therapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Segmental Outlook

On the basis of product type, the global neonatal surfactant therapy market is segregated into animal-derived surfactant and synthetic surfactant. The animal-derived surfactant segment is projected to hold a significant share of the market during the forecast period, as it has superior efficacy compared to synthetic surfactants. Animal-derived surfactants have been used for decades in treating respiratory distress syndrome (RDS) in premature infants.

The synthetic surfactant segment is expected to expand at a rapid pace in the coming years, as manufacturing synthetic surfactants is potentially cheaper than obtaining them from animals. Second-generation synthetic surfactants have shown comparable effectiveness to animal-derived options, leading to increased adoption.

Get Free Sample Report

In terms of delivery method, the global neonatal surfactant therapy market is bifurcated into intratracheal instillation and minimally invasive techniques. The minimally invasive techniques segment is projected to hold a significant share of the market during the forecast period, as it is gentle on premature infants, minimizing the need for endotracheal intubation, and reducing potential damage to the fragile lungs. It reduces the incidence of complications such as pneumothorax (collapsed lung) and reduces the need for mechanical ventilation compared to intratracheal instillation.

The intratracheal instillation segment is expected to hold a substantial share of the market in the coming years, as it is a widely used method for delivering neonatal surfactant therapy. The intratracheal instillation method delivers the surfactant directly into the lungs, maximizing its effect on the alveoli.

Get Free Sample Report

Regional Outlook

On the basis of region, the global neonatal surfactant therapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The market in North America is projected to expand at a significant CAGR during the forecast period. The regional market growth is attributed to the increasing demand for neonatal surfactant therapy from hospitals.

The market in Asia Pacific is expected to expand at a rapid pace during the forecast period. The regional market growth is driven by the increasing prevalence of premature births in countries such as China and India.

The market in Europe is projected to expand at a substantial CAGR during the forecast period. Improved healthcare infrastructure and an increasing focus on neonatal treatments are key factors contributing to the growth of the market in the region.

Get Free Sample Report

Key Benefits for Industry Participants & Stakeholders

• In-depth Analysis of the Global Neonatal Surfactant Therapy Market

• Historical, Current, and Projected Market Size in terms of Value

• Potential & Niche Segments and Regions Exhibiting Promising Growth Covered

• Industry Drivers, Restraints, and Opportunities Covered in the Study

• Recent Industry Trends and Developments

• Competitive Landscape & Strategies of Key Players

• Neutral Perspective on Global Neonatal Surfactant Therapy market performance